Premium
Lornoxicam pharmacokinetics in the vitreous humor of albino rabbits
Author(s) -
TSIKA C,
TSOURDOU A,
TZATZARAKIS M,
TSILIMBARIS M,
PALLIKARIS IG
Publication year - 2009
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2009.2223.x
Subject(s) - lornoxicam , pharmacokinetics , high performance liquid chromatography , chromatography , drug , pharmacology , chemistry , medicine , ophthalmology , analgesic
Purpose To assess the elimination half‐life of intravitreal lornoxicam, a non‐steroidal anti‐inflammatory drug (NSAID). Methods Both eyes of 15 rabbits were intravitreally injected with 250 μg of commercially available lornoxicam (for intravenous/intramuscular use, Xefo® 8 IV/IM Injection, Nycomed Hellas S.A.). Six eyes were enucleated at time points 0, 1, 2, 6 and 24 hours after the injection was performed. The eyes were immediately frozen at ‐80°C. The vitreous was eviscerated from the eye and the drug was liquid‐liquid extracted from a 0.4 ml sample. Lornoxicam was isolated by a reversed‐phase High Performance Liquid Chromatography (HPLC) method at retention time 10.7 min and detected at 372 nm. The data were statistically analyzed in order to evaluate the pharmacokinetic parameters of the drug. Results The recovery of lornoxicam after liquid‐liquid extraction was calculated at 69.6% and the limit of determination was 0.1 μg/ml. Statistical analysis revealed that lornoxicam concentrations followed first‐order kinetics with an elimination rate constant of 0.235h‐1 and a half‐life of 3.0 h. Conclusion The determination of the pharmacokinetic characteristics of intravitreal lornoxicam allows the possibility for further investigation of the drug's intraocular behaviour and therapeutic potential.